Lipoxen to test pharma candidates with Russia's Pharmsynthez

Lipoxen has signed an agreement with Pharmsynthez, a private Russian research-based company, which will allow Pharmsynthez to apply Lipoxen's ImuXen and PolyXen technologies to six drug and vaccine candidates. Pharmsynthez will also fund clinical proof of concept trials which are planned to be completed by the end of next year.